United Therapeutics Corporation (UTHR)

$236.93

+1.62

(+0.69%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on United Therapeutics Corporation

  • Increasing Revenue

    Revenue is up for the last 5 quarters, 491.5M → 614.7M (in $), with an average increase of 5.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 267.6M → 217.1M (in $), with an average decrease of 18.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 43.5%

Performance

  • $234.31
    $240.70
    $236.93
    downward going graph

    1.11%

    Downside

    Day's Volatility :2.65%

    Upside

    1.56%

    downward going graph
  • $204.44
    $261.54
    $236.93
    downward going graph

    13.71%

    Downside

    52 Weeks Volatility :21.83%

    Upside

    9.41%

    downward going graph

Returns

PeriodUnited Therapeutics CorporationSector (Health Care)Index (Russel 2000)
3 Months
7.39%
-0.7%
0.0%
6 Months
2.17%
6.6%
0.0%
1 Year
3.22%
3.7%
-1.5%
3 Years
32.33%
14.0%
-21.8%

Highlights

Market Capitalization
11.1B
Book Value
$127.23
Earnings Per Share (EPS)
19.82
PE Ratio
11.69
PEG Ratio
7.8
Wall Street Target Price
292.25
Profit Margin
42.31%
Operating Margin TTM
42.49%
Return On Assets TTM
11.22%
Return On Equity TTM
18.27%
Revenue TTM
2.3B
Revenue Per Share TTM
49.73
Quarterly Revenue Growth YOY
25.1%
Gross Profit TTM
1.8B
EBITDA
1.2B
Diluted Eps TTM
19.82
Quarterly Earnings Growth YOY
0.63
EPS Estimate Current Year
24.04
EPS Estimate Next Year
24.86
EPS Estimate Current Quarter
4.19
EPS Estimate Next Quarter
5.3

Analyst Recommendation

Buy
    80%Buy
    10%Hold
    10%Sell
Based on 20 Wall street analysts offering stock ratings for United Therapeutics Corporation(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
14
14
Hold
2
2
2
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 23.35%

Current $236.93
Target $292.25

Company Financials

FY18Y/Y Change
Revenue
1.6B
↓ 5.65%
Net Income
589.2M
↑ 40.99%
Net Profit Margin
36.2%
↑ 11.98%
FY19Y/Y Change
Revenue
1.4B
↓ 11.0%
Net Income
-104.5M
↓ 117.74%
Net Profit Margin
-7.21%
↓ 43.41%
FY20Y/Y Change
Revenue
1.5B
↑ 2.38%
Net Income
514.8M
↓ 592.63%
Net Profit Margin
34.71%
↑ 41.92%
FY21Y/Y Change
Revenue
1.7B
↑ 13.63%
Net Income
475.8M
↓ 7.58%
Net Profit Margin
28.23%
↓ 6.48%
FY22Y/Y Change
Revenue
1.9B
↑ 14.88%
Net Income
727.3M
↑ 52.86%
Net Profit Margin
37.56%
↑ 9.33%
FY23Y/Y Change
Revenue
2.3B
↑ 20.2%
Net Income
984.8M
↑ 35.4%
Net Profit Margin
42.31%
↑ 4.75%
Q3 FY22Q/Q Change
Revenue
516.0M
↑ 10.52%
Net Income
239.3M
↑ 106.29%
Net Profit Margin
46.38%
↑ 21.54%
Q4 FY22Q/Q Change
Revenue
491.5M
↓ 4.75%
Net Income
132.1M
↓ 44.8%
Net Profit Margin
26.88%
↓ 19.5%
Q1 FY23Q/Q Change
Revenue
506.9M
↑ 3.13%
Net Income
240.9M
↑ 82.36%
Net Profit Margin
47.52%
↑ 20.64%
Q2 FY23Q/Q Change
Revenue
596.5M
↑ 17.68%
Net Income
259.2M
↑ 7.6%
Net Profit Margin
43.45%
↓ 4.07%
Q3 FY23Q/Q Change
Revenue
609.4M
↑ 2.16%
Net Income
267.6M
↑ 3.24%
Net Profit Margin
43.91%
↑ 0.46%
Q4 FY23Q/Q Change
Revenue
614.7M
↑ 0.87%
Net Income
217.1M
↓ 18.87%
Net Profit Margin
35.32%
↓ 8.59%
FY18Y/Y Change
Total Assets
3.4B
↑ 18.11%
Total Liabilities
612.4M
↓ 21.24%
FY19Y/Y Change
Total Assets
3.9B
↑ 15.07%
Total Liabilities
1.1B
↑ 85.01%
FY20Y/Y Change
Total Assets
4.6B
↑ 17.93%
Total Liabilities
1.2B
↑ 7.66%
FY21Y/Y Change
Total Assets
5.2B
↑ 12.01%
Total Liabilities
1.2B
↓ 0.79%
FY22Y/Y Change
Total Assets
6.0B
↑ 16.94%
Total Liabilities
1.2B
↑ 3.11%
FY23Y/Y Change
Total Assets
7.2B
↑ 18.57%
Total Liabilities
1.2B
↓ 5.26%
Q3 FY22Q/Q Change
Total Assets
5.8B
↑ 4.3%
Total Liabilities
1.2B
↓ 0.45%
Q4 FY22Q/Q Change
Total Assets
6.0B
↑ 4.55%
Total Liabilities
1.2B
↑ 2.33%
Q1 FY23Q/Q Change
Total Assets
6.3B
↑ 4.99%
Total Liabilities
1.2B
↓ 2.0%
Q2 FY23Q/Q Change
Total Assets
6.7B
↑ 5.28%
Total Liabilities
1.3B
↑ 3.88%
Q3 FY23Q/Q Change
Total Assets
7.0B
↑ 5.12%
Total Liabilities
1.3B
↑ 3.24%
Q4 FY23Q/Q Change
Total Assets
7.2B
↑ 2.04%
Total Liabilities
1.2B
↓ 9.86%
FY18Y/Y Change
Operating Cash Flow
778.4M
↑ 64.15%
Investing Cash Flow
-820.6M
↓ 1.8%
Financing Cash Flow
6.3M
↓ 85.45%
FY19Y/Y Change
Operating Cash Flow
-206.6M
↓ 126.54%
Investing Cash Flow
-335.4M
↓ 59.13%
Financing Cash Flow
611.2M
↑ 9601.59%
FY20Y/Y Change
Operating Cash Flow
755.7M
↓ 465.78%
Investing Cash Flow
-738.5M
↑ 120.18%
Financing Cash Flow
-16.9M
↓ 102.77%
FY21Y/Y Change
Operating Cash Flow
598.2M
↓ 20.84%
Investing Cash Flow
-486.9M
↓ 34.07%
Financing Cash Flow
44.8M
↓ 365.09%
FY22Y/Y Change
Operating Cash Flow
802.5M
↑ 34.15%
Investing Cash Flow
-811.5M
↑ 66.67%
Financing Cash Flow
75.4M
↑ 68.3%
Q3 FY22Q/Q Change
Operating Cash Flow
258.6M
↑ 103.62%
Investing Cash Flow
-94.0M
↓ 44.38%
Financing Cash Flow
7.0M
↓ 70.71%
Q4 FY22Q/Q Change
Operating Cash Flow
128.2M
↓ 50.43%
Investing Cash Flow
-189.3M
↑ 101.38%
Financing Cash Flow
55.5M
↑ 692.86%
Q1 FY23Q/Q Change
Operating Cash Flow
374.8M
↑ 192.36%
Investing Cash Flow
-221.1M
↑ 16.8%
Financing Cash Flow
48.6M
↓ 12.43%
Q2 FY23Q/Q Change
Operating Cash Flow
106.3M
↓ 71.64%
Investing Cash Flow
-227.2M
↑ 2.76%
Financing Cash Flow
24.7M
↓ 49.18%

Technicals Summary

Sell

Neutral

Buy

United Therapeutics Corporation is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
United Therapeutics Corporation
United Therapeutics Corporation
0.57%
2.17%
3.22%
32.33%
32.33%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
United Therapeutics Corporation
United Therapeutics Corporation
11.69
11.69
7.8
24.04
0.18
0.11
NA
127.23
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
United Therapeutics Corporation
United Therapeutics Corporation
Buy
$11.1B
32.33%
11.69
42.31%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • BlackRock Inc

    11.25%

  • Vanguard Group Inc

    9.93%

  • Wellington Management Company LLP

    8.06%

  • venBio Select Advisor LLC

    6.08%

  • FMR Inc

    4.93%

  • Renaissance Technologies Corp

    4.61%

Company Information

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians

Organization
United Therapeutics Corporation
Employees
1168
CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Industry
Health Technology

Discover More

FAQs